Voyager Therapeutics (NASDAQ:VYGR) Given “Outperform” Rating at Wedbush

Wedbush reiterated their outperform rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Wednesday morning,Benzinga reports.

VYGR has been the topic of several other research reports. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Monday, March 3rd. Finally, Citigroup initiated coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price on the stock. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $15.08.

Voyager Therapeutics Stock Performance

VYGR stock opened at $4.06 on Wednesday. The company has a market capitalization of $221.78 million, a P/E ratio of 5.72 and a beta of 0.99. Voyager Therapeutics has a 52-week low of $3.56 and a 52-week high of $10.66. The business has a 50-day simple moving average of $4.95 and a two-hundred day simple moving average of $5.87.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. During the same quarter last year, the firm posted $1.25 EPS. As a group, sell-side analysts forecast that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 10,778 shares of company stock worth $58,548. Corporate insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after acquiring an additional 6,740 shares in the last quarter. FMR LLC grew its position in Voyager Therapeutics by 26.9% in the third quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after acquiring an additional 19,622 shares in the last quarter. Barclays PLC grew its position in Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after acquiring an additional 37,398 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in Voyager Therapeutics by 23.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock worth $223,000 after acquiring an additional 7,573 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new stake in Voyager Therapeutics during the third quarter valued at about $216,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.